NCT04273555View on ClinicalTrials.gov

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients with Advanced PET/MR Imaging

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

[18F]-FDG

\[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.

Trial Locations (1)

35249

RECRUITING

The University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER